Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-A3334 alone or with anlotinib in advanced NSCLC
NCT04273815Phase 2Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jul 2020
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of tq-a3334 in non-small cell lung cancer (NSCLC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Adverse events (AE) at 21 days, Dose limited toxicity at 21 days and 1 more. Status: unknown.
02
Drugs
tq-a3334
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04273815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04273815.